SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Faderl S, Jeha S, Kantarjian H. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003; 98: 13371354.
  • 2
    Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter study group for adult ALL (GMALL). Hematol/Oncol Clin North Am. 2000; 14: 13071325.
  • 3
    Durrant IJ, Richards SM, Prentice HG, Goldstone AH. The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol/Oncol Clin North Am. 2000; 14: 13271352.
  • 4
    Thiebaut A, Vernant JP, Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation: a follow-up report of the French protocol LALA 87. Hematol/Oncol Clin North Am. 2000; 14: 13531365.
  • 5
    Larson RA. Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol/Oncol Clin North Am. 2000; 14: 13671379.
  • 6
    Garcia-Manero G, Kantarjian H. The Hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol/Oncol Clin North Am. 2000; 14: 13811396.
  • 7
    Linker CA, Levitt LJ, O'Donnell M, et al. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood. 1991; 78: 28142822.
  • 8
    Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000; 18: 547561.
  • 9
    Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM. Philadelphia chromosome-positive acute lymphoblastic leukemia—current concepts and future perspectives. Rev Clin Exp Hematol. 2002; 6: 142160.
  • 10
    Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004; 103: 43964407.
  • 11
    Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol. 1990; 8: 9941004.
  • 12
    Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood. 1999; 93: 39833993.
  • 13
    Goldstone AH, Prentice HG, Durant J, et al. Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Results from the International ALL Trial (MRC UKALLXII/ECOG E2933) [abstract]. Blood. 2001; 98: 856a.
  • 14
    Goldstone A, Chopra R, Buck G, et al. The outcome of 267 Philadelphia positive adults in the International UKALL12/ECOG E 2993 study. Final analysis and the role of allogeneic transplant in those under 50 years [abstract]. Blood. 2003; 102: 80a
  • 15
    Barrett A, Horowitz M, Ash R, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1992; 79: 30673070.
  • 16
    Hoelzer D. Which factors influence the different outcome of therapy in adults and children with ALL? Bone Marrow Transplant. 1989; 4(Suppl. 1): 98100.
  • 17
    Zang M, Hoelzer D, Horowitz M, et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. Ann Intern Med. 1995; 123: 428431.
  • 18
    Sebban C, Lepage E, Vernant J, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. J Clin Oncol. 1994; 12: 25802587.
  • 19
    Rowe JM, Richards S, Burnett AK, et al. Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): results from the International ALL Trial (MRC UKALL XII/ECOG E2993) [abstract]. Blood. 2001; 98: 481a.
  • 20
    Nachman J, Sather H, Cherlow J, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: A report from the Children's Cancer Group. J Clin Oncol. 1998; 16: 920930.
  • 21
    Bürger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003; 21: 184188.
  • 22
    Pui C-H, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003; 349: 640649.
  • 23
    Walter A, Hancock M, Pui C-H, et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St. Jude children's Research Hospital. J Clin Oncol. 1998; 16: 37613767.
  • 24
    Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003; 101: 38093817.
  • 25
    Norwak-Göttl U, Ahlke E, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood. 2003; 101: 25292533.
  • 26
    Schwartz C, Thompson EB, Gelber R, et al. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol. 2001; 19: 10401046.
  • 27
    Pui C-H, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998; 339: 605615.
  • 28
    Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90—German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000; 95: 33103322.
  • 29
    Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana Farber Consortium Protocol 91-01. Blood. 2001; 97: 12111218.
  • 30
    Nachman JB, Harland NS, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998; 338: 16631671.
  • 31
    Stock W, Sather HN, Dodge RK. Outcome of adolescents and young adults with ALL: a comparison of Children's Cancer Group (CCG) and Cancer and Leukemia Group B (CALGB) regimens [abstract]. Blood. 2000; 96: 467a.
  • 32
    Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003; 21: 774780.
  • 33
    Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol. 2003; 21: 760761.
  • 34
    Peeters M, Koren G, Jakubovicz D, et al. Physician compliance and relapse rates of acute lymphoblastic leukemia in children. Clin Pharmacol Ther. 1988; 43: 228232.
  • 35
    Eden OB, Stiller CA, Gerrard MP. Improved survival for childhood acute lymphoblastic leukemia: possible effect of protocol compliance. Pediatr Hematol Oncol. 1988; 5: 8391.
  • 36
    Chessells J, Hall E, Prentice H, et al. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia. 1998; 12: 463473.
  • 37
    Hoelzer D, Thiel E, Löffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988; 71: 123131.
  • 38
    Taylor PRA, Reid MM, Brown N, Hamilton PJ, Proctor SJ. Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome. Blood. 1992; 80: 18131817.
  • 39
    Toyoda Y, Manabe A, Tsuchida M, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol. 2000; 18; 15081516.
  • 40
    Lauer S, Shuster J, Mahoney D, et al. A comparison of early intensive methotrexate/metcaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial. Leukemia. 2000; 15: 10381045.
  • 41
    Schmiegelow K, Björk O, Glomstein A, et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol. 2003; 21: 13321339.
  • 42
    Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood. 1995; 85: 20252037.
  • 43
    Stock W, Yu D, Johnson J, et al. Intensified daunorubicin during induction and post-remission therapy of adult acute lymphoblastic leukemia (ALL): results of CALGB 19802 [abstract]. Blood. 2003; 102: 379a.
  • 44
    Thomas D, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004; 104: 16241630.
  • 45
    Romaguera JE, Khouri IF, Kantarjian H, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000; 39: 19.
  • 46
    Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high dose methotrexate/cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle cell lymphoma. J Clin Oncol. 1998; 16: 38033809.
  • 47
    Dimopoulos MA, Weber D, Kantarjian H, et al. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol. 1996; 52: 7781.
  • 48
    Tsimberidou AM, Kantarjian H, Cortes J, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003; 97: 17111720.